Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.
From the U.S. FDA-approved label for Deferiprone. Full label: DailyMed.
Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate.
From the U.S. FDA-approved label for Deferiprone. Full label: DailyMed.
Deferiprone Tablets are available in a 1,000 mg formulation., To prevent medication errors, before prescribing and dispensing, ensure that the tablet formulation is appropriate for the dosing regimen.
Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.
Deferiprone tablets are contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulation. The following reactions have been reported in association with the administration of deferiprone: Henoch-Schönlein purpura; urticaria; and periorbital edema with skin rash. Hypersensitivity to deferiprone or to any of the excipients in the formulations.
Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.
Liver Enzyme Elevations: Monitor monthly and discontinue for persistent elevations., Zinc Deficiency: Monitor during therapy and supplement for deficiency., Embryo-Fetal Toxicity: Can cause fetal harm. 5.1 Agranulocytosis and Neutropenia Fatal agranulocytosis can occur with deferiprone tablets use. Deferiprone tablets can also cause neutropenia, which may foreshadow agranulocytosis. Measure the absolute neutrophil count (ANC) before starting deferiprone tablets therapy and monitor it regularly while on therapy.
Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.
The following clinically significant adverse reactions are described below and elsewhere in the labeling: Agranulocytosis and Neutropenia, Liver Enzyme Elevations, Zinc Deficiency, The most common adverse reactions in patients with thalassemia (incidence ≥ 6%) are nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia. To report SUSPECTED ADVERSE REACTIONS, contact Hikma Pharmaceuticals USA Inc.
Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.
2 products from 1 maker in the NepalDoc medicine catalog use this generic:
| Brand | Composition | Maker | Pack |
|---|---|---|---|
| Kelfer 250 Capsule | Deferiprone (250mg) | Cipla Ltd | bottle of 50 capsules |
| Kelfer 500 Capsule | Deferiprone (500mg) | Cipla Ltd | bottle of 50 capsules |
Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.
Storage: Store at 20° to 25°C (68° to 77°F); Keep the bottle tightly closed to protect from moisture.
Storage information from the U.S. FDA-approved label.
This page is information only and is not medical advice. Medicine details come from the sources listed above and may change — always confirm the medicine, strength and dose with a pharmacist or doctor before use. NLEM listing does not guarantee that a medicine is in stock at any pharmacy.
